Return to search results
Lazertinib
Lazcluze (lazertinib) is an oral prescription tablet medication classified as a kinase inhibitor. It is available in 80mg and 240mg strengths and is manufactured by Janssen Biotech, Inc. for treating specific conditions like certain cancers. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Lazcluze (lazertinib) is an oral prescription tablet medication classified as a kinase inhibitor. It is available in 80mg and 240mg strengths and is manufactured by Janssen Biotech, Inc. for treating specific conditions like certain cancers. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Lazertinib",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Lazertinib — ANDA 219008 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219008"
}
]
|
| identifier | ANDA219008 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-information",
"drug-safety",
"medications",
"prescription-drugs"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Lazertinib |
